CAJ | 학술논문

目的：评价美常安联合六味安消治疗慢性功能性便秘的疗效。方法慢性功能性便秘患者89例，采用平行、双盲、随机的方法分为三组，A 组（n=31）口服美常安+六味安消，B 组（n=30）口服美常安，C 组（n=28）口服六味安消，治疗疗程为4周。结果治疗4周后，三组总缓解率分别为96.77%，53.33%，57.14%，A 组显著高于 B 和 C 两组（P ＜0.05）。结论美常安联合六味安消治疗慢性功能性便秘优于单用一种药物，且效果明显，安全有效，值得临床推广应用。
목적：평개미상안연합륙미안소치료만성공능성편비적료효。방법만성공능성편비환자89례，채용평행、쌍맹、수궤적방법분위삼조，A 조（n=31）구복미상안+륙미안소，B 조（n=30）구복미상안，C 조（n=28）구복륙미안소，치료료정위4주。결과치료4주후，삼조총완해솔분별위96.77%，53.33%，57.14%，A 조현저고우 B 화 C 량조（P ＜0.05）。결론미상안연합륙미안소치료만성공능성편비우우단용일충약물，차효과명현，안전유효，치득림상추엄응용。
Objective To evaluate abstract the therapeutic effects of Medilac-S combined with Liuwei-Anxiao on chronic functional constipation. Methods 89 patients with chronic functional constipation were randomly divided into 3 groups: Medilac-S plus Liuwei-Anxiao group(A,n=31),Medilac-S group(B,n=30), Liuwei-Anxiao group(C,n=28),the treatment lasted for 4 weeks.Results After 4 weeks of treatment, the total remission rates were 96.77%, 53.33%, 57.14% respectively in group A, B and C, A group was significantly higher than that of B and C groups (P<0.05).Conclusion Combined use of Medilac-S with Liuwei-Anxiao on chronic functional constipation is better than one drug alone, and the results are obvious, safe,and effective, worthy of clinical application.